Marcelo C. Pasquini, MD | Authors

Articles

Analyzing Real-World Data for CAR T-Cell Therapy in Patients With ALL and DLBCL

October 07, 2019

Marcelo C. Pasquini, MD, discusses the rationale for analyzing real-world data for the use of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma. This CD19 CAR T cell was approved 2 years ago for use in both ALL and DLBCL.